Indopoly Swakarsa Industry Tbk vs Organon Pharma Indonesia Tbk. — how do they compare? Indopoly Swakarsa Industry Tbk trades at Rp115 (market cap 747.43B, 851.1K 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Indopoly Swakarsa Industry Tbk is far larger — about 7.2× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| IPOL | SCPI | |
|---|---|---|
Market Cap | 747.43B | 104.4B |
Volume | 851.1K | — |
Lot | 8.51K | — |
Turnover | 98.07M | — |
Average Price | 115.23 | — |
Value | 98.07M | — |
Indicative Equilibrium Price | 115 | — |
Indicative Equilibrium Volume | 47 | — |
Trailing returns across standard periods
Latest headlines on both assets
PT Indopoly Swakarsa Industry (the company) was established on 24 Mar 1995 based on Notaries Deed No. 114 and the deed of establishment was approved by the the Ministry of Justice dated Dec 22, 1995. The Company’s articles of association has been amended several times, most recently by notarial deed No. 5 of Popie Savitri, S.H., dated Mar 1, 2010, concerning among others, the change in the Company’s name, and public offering.
Read more on IPOL →PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →